Navigation Links
Par Pharmaceutical Begins Shipment of Generic Rythmol SR®

WOODCLIFF LAKE, N.J., Jan. 3, 2011 /PRNewswire/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it began shipping the 225mg, 325mg, and 425mg strengths of propafenone SR capsules, the generic version of GlaxoSmithKline's Rythmol SR®.  Par has been awarded 180 days of marketing exclusivity, commencing at launch, for being the first to file an ANDA containing a paragraph IV certification for the product.  According to IMS Health data, annual sales in the U.S. of Rythmol are approximately $121 million.

Important information about propafenone SR capsules

Propafenone extended release capsules are indicated to prolong the time to recurrence of symptomatic atrial fibrillation in patients without structural heart disease.

The use of propafenone extended release capsules in patients with permanent atrial fibrillation or in patients exclusively with atrial flutter or PSVT has not been evaluated.  Propafenone extended release capsules should not be used to control ventricular rate during atrial fibrillation.

The effect of propafenone extended release capsules on mortality has not been determined (refer to full prescribing information for black box WARNINGS).

Propafenone extended release capsules are contraindicated in the presence of congestive heart failure, cardiogenic shock, sinoatrial, atrioventricular and intraventricular disorders of impulse generation or conduction (e.g., sick sinus node syndrome, atrioventricular block) in the absence of an artificial pacemaker, bradycardia, marked hypotension, bronchospastic disorders, electrolyte imbalance, or hypersensitivity to the drug.

About Par Pharmaceutical Companies, Inc.

Par Pharmaceutical Companies, Inc. is a U.S.-based specialty pharmaceutical company.  Through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals, it develops, manufactures and markets higher-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals.  For press releases and other company information, visit

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein.  Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's most recent Annual Report on Form 10-K, in other of the Company's filings with the SEC from time to time, including Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and on general industry and economic conditions.  Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
(Date:10/12/2015)... -- Use this report to: - Learn ... the medical membrane devices market. - Analyze the present ... medical membrane devices market including hemodialyzers, membrane oxygenators, intravenous ... devices. - Gain information on newly approved products, recalls ... Use this report to: - Learn about the performance, ...
(Date:10/12/2015)... and CRANBURY, N.J. , Oct. ... LLP announces that a securities fraud class ... for the District of New Jersey.  The complaint alleges ... FOLD) violated the Securities Exchange Act of 1934 between ... materially false and misleading statements about Amicus Therapeutics, business ...
(Date:10/12/2015)... , Oct. 12, 2015  MiMedx Group, Inc. ... utilizing human amniotic tissue and patent-protected processes to develop ... Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and the ... results for the third quarter of 2015, its guidance ... Company has secured a $50 million Senior Secured Credit ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... ... first commercially-available next-generation sequencing laboratory test for bacterial vaginosis- a significant women's ... in Vancouver, BC, Canada. , In a presentation entitled: "The Microbiome ...
(Date:10/12/2015)... ... October 13, 2015 , ... Career Step, ... the release of its new Professional Medical Coding and Billing with Applied PCS ... ICD-10-CM and ICD-10-PCS code sets, earn the Certified Professional Coder (CPC) and Certified ...
(Date:10/12/2015)... ... 12, 2015 , ... According to an article from ... particularly in the area of track and field, are at a significantly higher ... peers in the same age group. Dr. Steven Meier of Meier Orthopedic Sports ...
(Date:10/12/2015)... ... 12, 2015 , ... According to an article published by Texas ... Texas recommended that any high-rises in the city limits that do not have fire ... article explains that it wasn’t until 1982 that the city started requiring fire sprinklers ...
(Date:10/12/2015)... ... October 12, 2015 , ... AcousticSheep LLC, creators of the ... honor of Breast Cancer Awareness Month. During the month of October, for ... SleepPhones® Classic product to a breast cancer patient at the Cleveland Clinic. , ...
Breaking Medicine News(10 mins):